GLP1R and obesity due to melanocortin 4 receptor deficiency: Despite their origin as incretin-based therapies for type 2 diabetes and obesity, several GLP-1 analogues have demonstrated CNS effects that suggest, either directly or indirectly, interaction with brain targets.